阿托伐他汀减少冠脉介入治疗引起心肌损伤的研究

Research of Atorvastation in Reducing Myocardial Injure After Coronary Arterial Intervention

目的研究他汀类药物能否减少冠脉介入治疗(PCI)带来的心肌坏死。方法在PCI术前7 d随机给予阿托伐他汀40 mg/d或者安慰剂口服,在术前和术后8 h、24 h检测CK-MB、肌钙蛋白Ⅰ型和肌红蛋白。结果PCI术后心肌损伤的标记物升高,在阿托伐他汀组升高的人数明显低于安慰剂组,PCI术后酶学峰值升高在阿托伐他汀组比安慰剂组减低。结论在PCI术前7 d给予阿托伐他汀40 mg/d能明显减少心肌损伤。

Objective To study the effect of atorvastation in reduction of myocardial injury during percutaneous coronary intervention （PCI）. Methods The two treatment groups were received atorvastation 40mg daily or placebo in 7 successive days before PCI, and OK MB, cardiac troponin and myoglobin were monitored before and 4 and 24 hours after the procedure. Results The myocardial injury markers were elevated after PCI, however, both the number of ascended patients and the ascended peak value of enzyme in the atrovastatin treatment group were signigicantly lower than those of the placebo group. Conclusion Administering 40mg atorvastation dialy in 7 successive days before POl can significantly reduce the myocardial injury.